Moderna (MRNA) said Wednesday that it has voluntarily withdrawn its Biologics License Application for mRNA-1083, its flu and COVID combination vaccine candidate for adults aged 50 and older.
The biotech firm said it will resubmit the BLA after vaccine efficacy data from a late-stage trial of its investigational seasonal influenza vaccine mRNA-1010 are available.
Moderna said it expects interim data from the mRNA-1010 trial to be available this summer.
The decision to withdraw the license was made in consultation with the US Food and Drug Administration, the company said.
Shares of Moderna were down 1.4% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.